RecruitingNCT06076200

Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations

Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations With High Risk for EOS

Sponsor

Shandong University

Enrollment

50 participants

Start Date

Sep 30, 2023

Study Type

OBSERVATIONAL

Conditions

Early-Onset Neonatal Sepsis

Summary

The purpose of this study is to describe the population pharmacokinetic characteristics of piperacillin/tazobactam after intravenous administration in pregnant women during pregnancy and delivery, and to evaluate pharmacodynamic effectiveness and safety of piperacillin/tazobactam in pregnant women whose baby are at high risk of developing early-onset sepsis after birth.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Piperacillin Sodium and Tazobactam Sodium for Injection for people with early-onset neonatal sepsis. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPiperacillin Sodium and Tazobactam Sodium for Injection

Piperacillin/Tazobactam, specification: 4g; 0.5g. Anti-infective therapy with piperacillin/tazobactam, specific regimen based on clinical practice, without intervention.

Locations(1)

Shandong Provincial Hospital

Jinan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06076200

Related Trials

Presepsin to Safely Reduce Antibiotics in Preterm Infants

NCT061006141 location